Chiome Bioscience Inc. Logo

Chiome Bioscience Inc.

Clinical-stage biotech developing therapeutic antibodies and providing R&D services to partners.

4583 | T

Overview

Corporate Details

ISIN(s):
JP3205350006
LEI:
Country:
Japan
Address:
渋谷区本町三丁目12番1号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Chiome Bioscience Inc. is a clinical-stage biotechnology company established in 2005, specializing in the research and development of therapeutic antibodies. The company focuses on addressing unmet medical needs by creating innovative antibody-based drugs. It utilizes a portfolio of proprietary technologies, most notably its ADLib® system, to accelerate the discovery and selection of optimal antibody candidates for its drug pipeline. Chiome Bioscience is engaged in advancing its own therapeutic programs and providing antibody development support and services to partners in the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-12 09:05
Report Publication Announcement
確認書
Japanese 8.3 KB
2025-08-12 09:04
Interim Report
半期報告書-第22期(2025/01/01-2025/12/31)
Japanese 188.7 KB
2025-03-28 08:09
Governance Information
内部統制報告書-第21期(2024/01/01-2024/12/31)
Japanese 22.8 KB
2025-03-28 08:07
Registration Form
確認書
Japanese 8.3 KB
2025-03-28 08:05
Annual Report
有価証券報告書-第21期(2024/01/01-2024/12/31)
Japanese 1.6 MB
2025-03-28 08:03
Post-Annual General Meeting Information
臨時報告書
Japanese 30.6 KB
2025-02-19 08:04
Audit Report / Information
臨時報告書
Japanese 19.7 KB
2024-11-15 07:48
Registration Form
確認書
Japanese 8.4 KB
2024-11-15 07:45
Annual Report
訂正有価証券報告書-第20期(2023/01/01-2023/12/31)
Japanese 767.5 KB
2024-08-13 09:10
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-08-13 09:08
Interim Report
半期報告書-第21期(2024/01/01-2024/12/31)
Japanese 226.8 KB
2024-07-05 08:02
Registration Form
有価証券届出書(組込方式)
Japanese 264.6 KB
2024-05-14 09:12
Quarterly Report
四半期報告書-第21期第1四半期(2024/01/01-2024/03/31)
Japanese 185.2 KB
2024-05-14 09:12
Report Publication Announcement
確認書
Japanese 8.3 KB
2024-03-26 08:50
Post-Annual General Meeting Information
臨時報告書
Japanese 23.1 KB

Automate Your Workflow. Get a real-time feed of all Chiome Bioscience Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chiome Bioscience Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chiome Bioscience Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Atomera Inc Logo
Licenses semiconductor material and IP to enhance transistor performance and power efficiency.
United States of America
ATOM
Atrae, Inc. Logo
Develops People Tech solutions for HR, including big data job sites and organizational analytics.
Japan
6194
Developing uranium and battery minerals for the nuclear energy and energy storage markets.
Australia
AEE
Avalo Therapeutics, Inc. Logo
Clinical-stage biotech developing IL-1β therapies for immune inflammatory diseases.
United States of America
AVTX
AVIS BUDGET GROUP, INC. Logo
Global provider of car rental, truck rental, and car-sharing for business & leisure travelers.
United States of America
CAR
Azenta, Inc. Logo
Life science solutions for pharma & biotech, offering sample management, storage & multiomics.
United States of America
AZTA
BayCurrent, Inc. Logo
Comprehensive consulting on strategy, AI, and digital transformation for corporations and government.
Japan
6532
BenevolentAI Logo
An AI-powered drug discovery platform accelerating R&D for scientists and pharmaceutical partners.
United Kingdom
BAI
BerGenBio Logo
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
Norway
BGBIO
Bergman & Beving Logo
Acquires and develops niche companies with solutions for the industrial and construction sectors.
Sweden
BERG

Talk to a Data Expert

Have a question? We'll get back to you promptly.